UK Seeks Smooth 'Grandfathering' Of EU Centrally Approved Drugs In Event Of No-Deal Brexit

In preparation for a possible no-deal Brexit, the UK medicines regulator is pressing on with its plans to facilitate the automatic conversion of EU centrally authorized products to UK marketing authorizations. Affected sponsors are being asked to undertake certain actions to ensure the process runs smoothly.